The mycobiome is the fungal component of the microbiome, the community of fungi that live on and inside the human body alongside the far more studied bacteria and viruses. These fungi inhabit the oral cavity, gastrointestinal tract, respiratory tract, urogenital tract, and skin, and while they are vastly outnumbered by bacteria, they punch above their weight in shaping immune responses and disease risk.1PubMed Central. The Human Mycobiome: Colonization, Composition and the Role in Health and Disease Research on the mycobiome has lagged decades behind bacterial microbiome science, but the last ten years have brought a surge of findings connecting fungal communities to conditions ranging from inflammatory bowel disease to cancer to neuropsychiatric disorders.
What Lives Where
Different body sites host strikingly different fungal communities. On the skin, a single genus dominates: Malassezia. This lipid-loving fungus thrives in oily areas like the scalp, face, and chest, and its lack of competition from other fungi suggests it has evolved to exploit the skin’s unique environment more efficiently than anything else.2PubMed. The skin mycobiome and intermicrobial interactions in the cutaneous niche Malassezia coexists with smaller populations of Candida and Rhodotorula, but these remain minor players under normal conditions.3PubMed Central. Fungal coexistence in the skin mycobiome: a study involving Malassezia, Candida, and Rhodotorula
The gut is more diverse. Resident fungal genera that can actually grow in the oxygen-poor, body-temperature environment of the intestines include Candida, Malassezia, and Cladosporium, drawn from the Ascomycota, Basidiomycota, and Zygomycota phyla.4PubMed Central. Effect of diet on the gut mycobiome and potential implications in inflammatory bowel disease But many fungi detected in stool are simply passing through, swallowed with food or inhaled and swallowed with mucus. Researchers distinguish between these transient species and the smaller group of true residents that colonize the gut wall and interact with the immune system. Large population studies find Saccharomyces and Candida among the most commonly detected genera, alongside plant-associated fungi like Sporisorium that likely arrive via the diet.5PubMed Central. Host Factors Associated with Gut Mycobiome Structure
The vaginal mycobiome, though a small part of the cervicovaginal ecosystem, matters for reproductive health.6PubMed Central. Environmental fungi modulate the vaginal mycobiome and cervical disease progression in Hispanic women Candida albicans colonizes roughly 20% of women without causing symptoms, yet it remains one of the leading causes of vaginal infections when conditions shift in its favor.7PubMed Central. The vaginal mycobiome: A contemporary perspective on fungi in women’s health and diseases In the lungs, fungal communities have been linked to the progression of chronic respiratory diseases including COPD, asthma, bronchiectasis, and cystic fibrosis.8PubMed Central. The airway mycobiome in chronic respiratory diseases: current advances and future frontiers
How Diet and Geography Shape Your Fungal Communities
Your gut mycobiome is not fixed. It shifts with what you eat, where you live, and how you live. In a large study examining host factors that correlate with gut fungal variation, diet-related variables topped the list. Consumption of chips, meat, sodas, sweeteners, processed foods, and alcohol all correlated with changes in fungal community structure, followed by age and even marital status.9PubMed Central. Host Factors Associated with Gut Mycobiome Structure The finding about marital status sounds odd at first, but it probably reflects shared meals and living environments rather than anything romantic about fungi.
Geography and urbanization leave an even deeper imprint. A study comparing gut mycobiomes across six ethnic groups in urban and rural China found that urbanization-related factors had the strongest impact on fungal variation, followed by geography, diet, and ethnicity.10PubMed. Population-Level Configurations of Gut Mycobiome Across 6 Ethnicities in Urban and Rural China People in highly urbanized Hong Kong had significantly fewer fungal species compared to rural populations in Yunnan province, with a mean fungal richness of 38 species versus 55. Urban populations also showed a depletion of beneficial symbiotic fungi and a higher proportion of saprotrophic and pathogenic fungi. Across ethnic groups, the genus Saccharomyces was consistently enriched in urban residents, while rural populations harbored a richer array of diverse fungal genera.11PubMed Central. Human gut mycobiome varies across geography, ethnicity, and urbanisation This echoes a broader pattern seen in bacterial microbiome research: modern, urbanized lifestyles tend to shrink microbial diversity, and the fungal kingdom is no exception.
Fungi and Bacteria Are Not Independent Roommates
One of the most important things to understand about the mycobiome is that fungi do not exist in isolation. They are in constant chemical and physical dialogue with the bacteria sharing their space. Researchers have described mechanisms by which bacteria govern fungal growth and virulence, as well as how fungi regulate bacterial pathogenesis, through chemical signals, physical contact, and protein-based interactions.12PubMed Central. Bacterial-fungal interactions and their impact on microbial pathogenesis These cross-kingdom interactions can either restrain disease or make it worse, depending on which organisms are present and in what proportions.
On the skin, for example, Malassezia’s dominance is partly maintained by its interactions with skin bacteria. When those bacterial communities are disrupted, as happens in atopic dermatitis or seborrheic dermatitis, the balance of the skin mycobiome shifts.13PubMed Central. Alteration in skin mycobiome due to atopic dermatitis and seborrheic dermatitis One emerging concern involves the pathogen Candida auris, which can displace Malassezia from the skin entirely, creating conditions that predispose to dangerous invasive infections.14PubMed. The skin mycobiome and intermicrobial interactions in the cutaneous niche In the vaginal tract, Lactobacillus bacteria normally keep Candida in check, and disruptions to that bacterial population play a key role in the progression from harmless Candida colonization to vulvovaginal candidiasis.15PubMed Central. Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC)
What Antibiotics Do to Fungi
Antibiotics target bacteria, but the collateral damage to the mycobiome is real and can last longer than the bacterial disruption. In one study tracking both bacterial and fungal communities after antibiotic treatment, the bacterial community recovered mostly within three months, but the fungal community underwent a more lasting transformation. Before antibiotics, the gut fungi and bacteria existed in a mutualistic relationship. After treatment, that relationship shifted to competition, and this competitive dynamic persisted well beyond the treatment period.16PubMed Central. Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria
The specific changes depend on which antibiotic is used. Amoxicillin-clavulanic acid, one of the most commonly prescribed antibiotics, triggered a decrease in the total fungal population in a mouse model, accompanied by a complete remodeling of which species were present. Genera like Aspergillus and Cladosporium became enriched, while others disappeared.17PubMed Central. Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem Other antibiotics had the opposite effect, increasing total fungal load. This explains something clinicians have long observed: antibiotic courses are a risk factor for fungal infections like oral thrush or vaginal yeast infections. The antibiotics suppress the bacteria that normally keep fungi in check, creating an opening for fungal overgrowth.
The Mycobiome in Inflammatory Bowel Disease
The gut mycobiome’s connection to inflammatory bowel disease (IBD) has attracted intense study, and a recent systematic review pulling together 27 case-control studies helps clarify what the evidence actually shows. Across roughly 1,400 IBD patients and 1,060 controls, the most consistent finding was an increase in Candida in both Crohn’s disease and ulcerative colitis, along with an increase in Malassezia specifically in Crohn’s disease. These increases were often accompanied by a decrease in Saccharomyces.18PubMed. Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies
The picture is not perfectly clean, though. Differences in fungal diversity between IBD patients and healthy controls varied by geographic region, and some studies found increased diversity while others found decreased diversity. What held up across most studies was that the overall composition of the fungal community differed between patients and controls, even when summary measures of diversity were inconsistent. The implication is that it’s not just about having more or fewer fungal species; it’s about which species dominate and how they interact with the immune system.
Fungi Inside Tumors
Perhaps the most surprising development in mycobiome research is the discovery that fungi live inside human tumors. Though present in very low abundance, fungi have been found to be ubiquitous across all major human cancer types, and distinct fungal communities have been identified in different tumor types.19PubMed Central. The tumor mycobiome: A paradigm shift in cancer pathogenesis Specific mycobiome profiles can even be predictive of patient survival, raising the possibility that tumor-associated fungi are not just passive bystanders but active participants in cancer biology.
A large study of over 1,000 renal cell carcinoma patients across four international cohorts explored this directly. Patients were divided into groups based on how much fungal material was present inside their tumors. Those with more abundant and diverse intratumoral fungi had worse outcomes, including poorer responses to immunotherapy. The researchers found that the fungal-rich tumors showed suppressed fat metabolism and exhausted immune T cells, both of which would help the tumor evade the immune system. A specific species, Aspergillus tanneri, emerged as a potential key player influencing prognosis.20PubMed Central. Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma
This field remains early-stage, and there are real analytical challenges. Fungi make up only an estimated 0.1 to 1% of the total microbiome, making them difficult to detect and distinguish from contamination. The diversity of methods used to study tumor-associated fungi has made it hard to compare results across studies.21PubMed Central. The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications Still, the basic finding that fungi are present and biologically active inside tumors has been replicated enough times that the research community is taking it seriously.
How the Mycobiome Develops in Infants
Babies are not born with a fully formed mycobiome, and how they acquire one is more complicated than it first appears. A study tracking mother-infant pairs found that offspring were more likely to have detectable fungal DNA in their stool if their mother did too, suggesting some degree of vertical transfer. Fungal diversity in the infant gut was lowest at 10 days after birth and gradually increased over time, with the species composition shifting to resemble the mother’s mycobiome as the child aged. During breastfeeding, the yeast Debaryomyces hansenii was most abundant; after weaning, Saccharomyces cerevisiae took over as the dominant species.22PubMed Central. Early gut mycobiota and mother-offspring transfer
But maternal transfer is not the whole story. A separate study found that infant mycobiomes were highly variable over the first month of life, and vaginal birth did not make infants’ fungal communities look more like their mother’s vaginal mycobiome. This suggests that while specific fungal strains can pass from mother to child, the environment, other caregivers, and other sources contribute substantially to early fungal colonization.23PubMed Central. Development of the Human Mycobiome over the First Month of Life and across Body Sites Unlike the bacterial microbiome, where birth mode (vaginal versus cesarean) has well-documented effects, the fungal community seems to take cues from a broader set of influences.
Fungi, the Gut, and the Brain
The gut-brain axis is a hot research area for bacteria, and fungi are now entering that conversation. The overgrowth of Candida albicans in the gut has been linked to chronic inflammatory states and increased gut permeability, a condition sometimes called “leaky gut.” When the gut barrier is compromised, fungal products like beta-glucans, molecules found in fungal cell walls, can trigger neuroinflammatory responses.24Frontiers in Cellular Neuroscience. Gut mycobiome and neuropsychiatric disorders: insights and therapeutic potential Research is exploring how the gut mycobiome may affect the blood-brain barrier’s integrity, the regulation of neurotransmitters, and immune signaling to the brain.25Advanced Gut & Microbiome Research. Exploring the Link Between the Gut Mycobiome and Neurological Disorders
This work is mostly at the mechanism-exploration stage rather than yielding clinical applications, but the basic logic is plausible: if gut fungi can alter immune signaling and gut barrier function, and if those signals reach the brain via the vagus nerve and immune pathways, then the mycobiome could contribute to neuropsychiatric conditions. Whether this turns into something therapeutically useful remains to be seen.
What Fungi Actually Produce
Part of why the mycobiome matters despite its small size is the sheer variety of molecules fungi generate. Fungi can break down carbohydrates, amino acids, lipids, proteins, and vitamins using both primary metabolism (for growth) and secondary metabolism (for survival and competitive advantage). This metabolic versatility creates ripple effects throughout the microbial ecosystem. One example: a fungal metabolite called N-acetyl-L-glutamic acid has blood-pressure-lowering effects, hinting that the mycobiome may influence cardiovascular health in ways we are only beginning to catalog.26PubMed Central. Host-mycobiome metabolic interactions in health and disease
These metabolic products also shape interactions with neighboring bacteria. The chemical signals fungi release can promote or inhibit bacterial growth, alter biofilm formation, and change how bacteria express virulence factors. The relationship works both ways: bacterial metabolites influence fungal behavior too. This chemical crosstalk means that studying either kingdom in isolation gives an incomplete picture of what is happening in any body site.
When Fungi Turn Dangerous
Most of the time, the fungi living in and on your body cause no trouble. But in people with weakened immune systems, from organ transplants, chemotherapy, HIV, or other causes, commensal fungi can turn invasive. Systemic Candida infections remain one of the most common hospital-acquired bloodstream infections in oncology settings, and Aspergillus fumigatus is the leading cause of invasive aspergillosis in transplant recipients. Broad-spectrum antibiotic use, with its disruption of the bacterial communities that normally keep fungi in check, is recognized as an important predisposing factor for these infections.27Indian Journal of Medical Specialities. The Human Mycobiome: Diagnostic Potential, Therapeutic Opportunities, and Future Directions
This is where the mycobiome concept becomes clinically concrete. Understanding which fungi normally live in the gut or lungs, what keeps them in a harmless state, and what tips them toward invasion is directly relevant to preventing the dangerous fungal infections that kill tens of thousands of immunocompromised patients each year. It also raises questions about whether routine antibiotic prescribing should account for fungal side effects more than it currently does.
Therapeutic Possibilities on the Horizon
If disrupted fungal communities contribute to disease, can restoring them help? Researchers are exploring several approaches: dietary interventions that favor beneficial fungi, fungal probiotics (analogous to bacterial probiotics), and fecal microbiota transplantation that includes fungal components alongside bacteria.28PubMed Central. Unveiling the overlooked fungi: the vital of gut fungi in inflammatory bowel disease and colorectal cancer Standard fecal transplant preparations already contain fungi, but they have not traditionally been characterized or optimized for their fungal content. That is starting to change as researchers recognize the mycobiome as an integral part of gut health that cannot be separated from the bacterial component.
Saccharomyces boulardii, a yeast already used as a probiotic supplement, is the best-known example of a therapeutic fungus. But the field is far from having a menu of targeted fungal therapies. The basic challenge is that we still do not know enough about what a “healthy” mycobiome looks like across different populations, ages, and geographies. The striking differences between urban and rural fungal communities, and between ethnic groups sharing the same region, make it clear that there is no single target composition to aim for. What the research has established is that fungi are not optional passengers in the microbiome. They are active participants in immune training, metabolic processing, and barrier function, and future therapies will need to account for them.